84 results about "Alpha protein" patented technology

There are disclosed topical compositions for alleviation of skin irritation symptoms or conditions having at least one plant extract effective to inhibit COX-2 enzyme, NGF protein, and/or TNF-alpha protein activity. Preferably, the compositions have a cosmetically, dermatologically, or pharmaceutically acceptable vehicle. In addition to the enzyme inhibitory plant material and acceptable vehicle, compositions may also have at least one active ingredient known to produce skin irritation. There is also a method for treatment of skin irritation symptoms or conditions involving topically applying compositions of the invention. Also disclosed are compositions and methods for topical administration of compositions to the skin that improve the aesthetic appearance of skin and/or provide an anti-aging benefit to the skin.

The invention discloses a kit for detecting active tuberculosis based on antigen-specific TNF-alpha-ELISA (enzyme linked immunosorbent assay) and an application thereof. The kit comprises an ELISA plate coating a TNF-alpha antibody, a TNF-alpha protein standard, protein liquid of ESAT-6 and CFP-10, a biotin-marked TNF-alpha antibody and avidin-marked horseradish peroxidase. By adopting the kit for detecting active tuberculosis based on TNF-alpha-ELISA, a method for distinguishing active tuberculosis infection from latent tuberculosis infection is established; the TNF-alpha released by the peripheral blood mononuclear cell under the stimulus of tuberculosis-specific antigens ESAT-6 and CFP-10 and the background TNF-alpha released by the peripheral blood mononuclear cell without stimulus are quantitatively detected through the ELISA technology, and the value of the antigen-specific TNF-alpha is obtained by subtracting the two so as to perform direct diagnosis on the active tuberculosis.

The invention relates to a fusion protein polymer. The fusion protein polymer consists of a component A and a component B, wherein the component A is a single domain antibody, while the component B is peptide sequences which perform multimerization on fusion protein and are derived from TNF alpha protein, ACRP30 protein, P53 protein, COMP protein, C4BP protein and mutants of the TNF alpha protein, the ACRP30 protein, the P53 protein, the COMP protein and the C4BP protein. The fusion protein polymer has the advantages of successful expression in Escherichia coli, high expression quantity, relatively simple preparation and low cost. Poly-antibodies of the fusion protein polymer have high dissolubility and biological activity and greatly improve the affinity of antibody protein. The fusion protein polymer can be prepared into various biotech products such as diagnostic reagents used for diagnosing melanoma and the like, and used for target treatment of the melanoma and the like by carrying a therapeutic medicament. When the poly-antibodies based on the fusion protein polymer are clinically applied, the problem of strong immunogenicity can be solved.

The present invention concerns a novel member of the tumor necrosis factor (TNF) family of cytokines. In particular, isolated nucleic acid molecules are provided encoding the endokine alpha protein. Endokine alpha polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic and therapeutic methods concerning TNF family-related disorders.

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutantER-alpha protein.

The invention relates to a method for detecting alpha-fetal protein on the basis of an RGO-CS-Fc/Au NPs nano composite material and aptamers. According to the method, the surface of a silk-screen printing electrode is modified with RGO-CS-Fc/Au NPs by means of an electro-deposition technology and an electrostatic adsorption effect; AFP aptamers are loaded on the surface of the RGO-CS-Fc/Au NPs bymeans of a nanotechnology and an intermolecular force, and the aptamers exist on the surface of the composite material in the form of single-chain structures due to the unstable spatial structures ofthe aptamers; after AFP is added into the surface of the electrode, the AFP can be specifically combined with the AFP aptamers, so that stable spatial structures can be generated, and therefore, the AFP and the aptamers can be orderly arranged on the surface of the electrode; a current value is detected through a DPV method, a relation curve of current and the concentration of the alpha-alpha protein is depicted; and therefore, the quantitative detection of the alpha-alpha protein is realized. The method has the advantages of simple operation, time-saving performance, low cost and low detection limit.

The invention provides a series of protein protective solutions which are capable of effectively protecting the activity of Hsp90 (Heat Shock Protein90) alpha protein and increasing the stability of the Hsp90alpha protein and are invariant under the concentration in nanogram level. On the basis of a traditional protein protectant, other protectant components are added in the protein protective solutions, and the other protectant components are selected from AMP (Adenosine Monophosphate), heparin sodium, MgCl2, PVP40 (Polyvinylpyrrolidone 40), tea polyphenol, cyclodextrin and K2SO4.

The present invention relates to novel engineered Ga proteins and assay methods of using such proteins to advance drug discovery. Engineered Ga proteins described by the invention contain alterations of at least one and preferably two or more amino acid residues that are highly conserved among all four subfamilies of Ga proteins. A preferred engineered protein disclosed here is a double mutant, Gαπ R178M A326S. This specific combination of mutations yields an unexpectedly amplified effect on Ga function both in terms of GTPase activity (GTP hydrolysis) and GDP dissociation. This synergistic effect may have a profound influence on the way GPCR signaling pathways are examined for the development of new pharmacotherapies, particularly in the field of central nervous system disorders such as Parkinson's disease.

The invention belongs to the technical field of biologic genetic engineering, and discloses a chicken alpha interferon (ChIFN-alpha)/interleukin 2(ChIL-2) chimeric gene, the technology comprises using an overlap extension PRC technique to constitute a mature peptide gene of the ChIFN-alpha and the ChIL-2 as a ChIFN-alpha-linker-ChIL-2 chimeric gene through a gene flexible linker (linker)(G4S), and cloning the constituted gene into a pGEM-TEasy carrier, subcloning the chimeric gene in a pQE-30 expression carrier to perform prokaryotic expression and perform rapid renaturation and purification to the expressed recombinant fusion protein. The activities of the purified rChIFN-alpha-liner-ChIL-2 fusion protein on the cell and in vitro and in vivo of the chicken are all provided with the superposition of the protein activity of the ChIFN-alpha and the ChIL-2, and the antiviral activity thereof is superior to the rChIFN-alpha protein. The chicken alpha interferon (ChIFN-alpha)interleukin 2(ChIL-2) chimeric gene is used as the main component of the antiviral preparation for preventing and treating the viral disease of the chicken, which is efficient, broad-spectrum, safe and low in cost.

The present invention concerns methods for diagnosis and treatment of metabolic bone diseases and disorders using a novel member of the tumor necrosis factor (TNF) family of cytokines. In particular the invention provides methods of using the Endokine alpha protein and/or homomultimeric and/or heteromultimeric polypeptide complexes containing Endokine alpha, in the diagnosis, prognosis and treatment of metabolic bone diseases and disorders. Also provided by the invention are methods of using the Endokine alpha protein and/or homomultimeric and/or heteromultimeric polypeptide complexes containing Endokine alpha, in the diagnosis, prognosis and treatment of diseases and/or disorders associated with aberrant osteoclast development and/or activity. The present invention also provides isolated polynucleotides encoding polypeptides of the invention, antibodies thereto, and agonists and antagonists thereof, for use in the diagnosis, prognosis and treatment of metabolic bone diseases and disorders.

The invention discloses a protein secondary structure prediction technology based on correlation analysis and correlation classification, wherein, based on a double-base cooperating mechanism, a KDD process model is introduced into the problem of protein secondary structure prediction; in a KAAPRO method, data mining (knowledge discovery) is used as a main body and Maradbcm arithmetic based on the KDD process model and a D-CBA method of correlation rule classification are adopted. The correlation rule obtained by the KAAPRO method discloses the influence relation of amino acid physical-chemical properties on the protein secondary structure, thus enhancing the precision of prediction. The characteristic of the Maradbcm arithmetic on mining accident rules mines the correlation rules of alpha protein base and beta protein base which have relatively high purity, therefore, the obtained mining results are the distillated rules. The D-CBA correlation classification method uses the measure of credibility and supportability as a composite measure for carrying out the protein correlation classification. While guaranteeing the prediction precision, the technology provides a basis for the further analysis of the secondary structure for biologists.

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutantER-alpha protein.

The invention discloses a human-mouse chimeric anti-CXCR2 full-molecule IgG and an application thereof and belongs to the field of biological pharmacy. The human-mouse chimeric anti-CXCR2 full-molecule IgG comprises a heavy chain variable region and a light chain variable region and is characterized in that the light chain variable region has a nucleic acid sequence shown in the formula of SEQ IDNO. 1 and the heavy chain variable region has a nucleic acid sequence shown in the formula of SEQ ID NO. 2. The mouse immunized by the specific recombinant CXCR2 protein is used, a mouse-derived anti-CXCR2 monoclonal antibody is prepared through a hybridoma technology, and the recombinant human-mouse chimeric anti-CXCR2 full-molecule IgG is prepared through genetic engineering and antibody engineering techniques. The chimeric antibody can effectively recognize the CXCR2 extracellular domain amino acid fragment and inhibit the binding of the CXCR2 protein to the GRO alpha protein.

The invention relates to angiogenesis of a triple mutant low-oxygen inducible factor 1 alpha induced by auxiliary activating factors and application thereof. The invention relates to the triple mutant low-oxygen inducible factor 1 alpha and a vector containing the triple mutant low-oxygen inducible factor 1 alpha for encoding nucleic acid, in particular a recombinant adenovirus vector and a medicinal composition containing the factor and the vector. Triple mutant HIF-1 alpha protein can be bound with the auxiliary activating factors such as response element binding protein (CREB)/adenovirus E1A associated protein P300 (CBP/p300), histone deacetylase (HDAC) and the like to promote expression of HIF-1 alpha downstream target genes such as a vascular endothelial growth factor (VEGF) and the like. The triple mutant protein, the nucleic acid, the vector and the medicinal composition are used for promoting angiogenesis and treating ischemic diseases such as coronary disease, peripheral artery ischemic vascular disease, intermittent claudication and the like.

The invention discloses a human stem cell growth factor as well as a production method and application of a polyethylene glycol (PEG) modified human stem cell growth factor. The production method comprises the following steps of: fusing an h-SCF (Stem Cell Factor)-alpha sequence and an SUMO (Small Ubiquitin-Related Modifier) sequence and constructing to obtain an SUMO-rhSCF-alpha fused gene expression vector; transferring the SUMO-rhSCF-alpha fused gene expression vector into a host bacteria to obtain engineering bacteria; culturing the engineering bacteria and inducing to express an SUMO-rhSCF-alpha fused protein; and cutting off an SUMO part to obtain an rhSCF-alpha protein. By using the production method, the high soluble expression and large-scale purification of the rhSCF-alpha protein in cell plasmas are realized, and the activity of the obtained rhSCF-alpha protein is high. The invention also discloses the production method of the PEG modified human stem cell growth factor; the half-life period of the PEG modified human stem cell growth factor obtained by using the method is remarkably prolonged, and the activity of the PEG modified human stem cell growth factor in promoting the proliferation of red blood cells is also remarkably improved; and the PEG modified human stem cell growth factor can be applied to the preparation of medicines for hypohemia therapy, reconstruction and recovery of a hematopoietic function after chemoradiotherapy and a bone marrow transplantation operation, stem cell ex-vivo expansion and gene therapy and cosmetics for promoting the metabolism of epidermal cells, repairing aged and damaged skin cells, delaying the aging of skin and the like.

The invention discloses recombinant alpha protein for inhibiting clostridium perfringens infection and a preparation method and application thereof. The recombinant alpha protein is shown in (a) or (b) or (c), wherein the protein in (a) is composed of amino acid sequences shown as SEQ ID No.2; the protein in (b) is composed of amino acid sequences shown at the sites No.51-No.353 of SEQ ID No.2; the fusion protein in (c) is obtained by fusing protein tags at carboxyl terminals or/and amino terminals of the protein shown in (a) or (b). The recombinant alpha protein enables animals to have a higher serum antibody level and resist attack of clostridium perfringens after the animals are immunized with the recombinant alpha protein. The recombinant alpha protein is good in solubility and easy to purify and can serve as a diagnostic antigen to be prepared into a monoclonal antibody or be used for further research on protein functions and conformation relations.

The invention discloses a method for screening an estrogen receptor Alpha (ER Alpha) single-chain antibody with a phage antibody library. The method comprises the following steps: using an ER Alpha protein as an immunogen for immunizing a New Zealand white rabbit and extracting total RNA of spleen; amplifying VH and VL fragments by RT-PCR, and splicing an scFv gene; constructing a PCANTAB5E-ScFv recombinant plasmid, electrotransforming E. coli TG1 competent cells with the recombinant plasmid to construct a phage single-chain antibody library; using ER Alph-positive breast cancer tissue sections and ER Alpha protein as solid phase antigens for performing affinity enrichment screening on the antibody library; and identifying positive clones with a method of combining a Phage-ElLSA method with breast cancer cell smear immunochemistry. The invention establishes a method for specifically screening ER from the phage antibody library by using the ER Alpha -positive breast cancer tissue sections, and identifying the positive clones with the method of combining the Phage-ElLSA method with the breast cancer cell smear immunochemistry, and provides a new idea for a phage antibody library screening method.

The invention discloses a mutant type TNF-alpha gene the base composition of which is shown as the SEQ ID NO 7, and discloses a method of increasing the expression quantity of the antigen TNF-alpha gene. The method includes steps of: amplifying by adopting a human secreting type TNF-alpha gene cDNA clone as a template and by adopting the SEQ ID NO 1 and the SEQ ID NO 2 as primers, so as to obtain an amplification product T1; amplifying by adopting the SEQ ID NO 3 and the SEQ ID NO 4 as primers, so as to obtain an amplification product T2; performing overlapping PCR amplification by adopting the amplification product T1 and the amplification product T2 as templates and adopting the SEQ ID NO 1 and the SEQ ID NO 4 as primers, so as to obtain the mutant type TNF-alpha gene; subjecting the mutant type TNF-alpha gene to double digestion; inserting into a pET28a expression vector; converting escherichia coli; and performing induced culture to obtain TNF-alpha protein. Two pairs of escherichia coli rare codons close with each other in the TNF-alpha gene mutant into escherichia coli optimal codons. The expression quantity of the TNF-alpha gene after the codon optimization is increased by at least 1.5 times.

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-alpha protein.

The invention provides a kit for detecting the prognosis of patients with esophageal squamous cell carcinoma in the Xinjiang region. The kit comprises a phospholipase epsilon 1 protein, an IKB alpha protein and a mutant P53 protein. The kit also comprises a citrate buffer solution with the content of 0.01M, an ethylenediaminetetraacetic acid repair solution with the content of 10mM, a H2O2 solution with the mass concentration of 3%, a phosphate buffer solution with the content of 0.01M, a BSA blocking solution with the mass concentration of 5%, an immunohistochemical Envision kit and a DAB developing reagent. The kit can forecast the prognosis of patients through detecting the expression case of the paraffin-embedded surgical specimen of the patients with esophageal squamous cell carcinomathrough PLCE1, IKB alpha and P53 proteins. Compared with the existing kit realizing single index detection, the kit has higher prediction effects and has the prediction ability similar to the TNM staged prediction ability. The two-step immunohistochemical method using the kit is a mature and reliable method that can be widely used in primary hospitals.

The invention provides a nucleotide sequence of a recombinant human tumor necrosis factor-Alpha, a method for efficiently producing the recombinant human tumor necrosis factor-Alpha and related techniques of construction, expression and purification of engineering cells. The optimized recombinant human tumor necrosis factor-Alpha protein gene is ideally suitable for being expressed in leaven, simultaneously, through the optimization of the ferment and purification techniques, the output thereof is increased and the advantages of high expression and high stability are realized. The invention can obtain the recombinant human tumor necrosis factor-Alpha pure products efficiently and conveniently with low cost.

The invention relates to a PHF14 C-terminal protein, its polyclonal antibody and an application thereof. According to the invention, human derived PHF14 C-terminal protein is separated, and it is found by chance that the antigen fragment has good immunogenicity. An antibody obtained from an antigen fragment immune animal can specifically identify PHF14 alpha protein instead of PHF14 beta fragment. The PHF14 C-terminal protein and its polyclonal antibody provided by the invention have advantages of simple preparation method, high titer, strong specificity and high sensitivity.